Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation - Full Text View

Purpose

The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy in patients given triple therapy for Helicobacter pylori eradication with Nexium + amoxicillin (AMPC) + clarithromycin (CAM), or Nexium + AMPC + metronidazole (MNZ) in usual post-marketing use.

Condition
Gastric Ulcer Duodenal Ulcer Gastric Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Idiopathic Thrombocytopenic Purpura Early Gastric Cancer


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	Nexium Capsules Specific Clinical Experience Investigation Concerning Helicobacter Pylori Eradication

Resource links provided by NLM:

Genetics Home Reference related topics: thrombotic thrombocytopenic purpura

Drug Information available for: Esomeprazole Esomeprazole Sodium Esomeprazole magnesium

Genetic and Rare Diseases Information Center resources: Idiopathic Thrombocytopenic Purpura Immune Thrombocytopenia Lymphosarcoma Stomach Carcinoma

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Number of Adverse Drug Reactions [ Time Frame: Period from the start of triple therapy to assessment of eradication, an expected average of 3 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Rate of H.Pylori eradication [ Time Frame: Period from the start of triple therapy to assessment of eradication, an expected average of 3 months ] [ Designated as safety issue: No ]


Enrollment:	369
Study Start Date:	September 2011
Study Completion Date:	March 2014
Primary Completion Date:	March 2014 (Final data collection date for primary outcome measure)

Groups/Cohorts
Nexium

Detailed Description:

Nexium capsules Specific Clinical Experience Investigation concerning Helicobacter pylori eradication

Eligibility


Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Patients to whom triple therapy for H.pylori eradication to stomach is started after endoscopic treatment for gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, or early gastric cancer as the approved indication of Nexium. Patients with H.pylori negative at the time when the triple therapy is started are excluded.

Criteria

Inclusion criteria:

Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for gastric ulcer
Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for duodenal ulcer
Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for gastric MALT lymphoma
Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for idiopathic thrombocytopenic purpura
Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for early gastric cancer

Exclusion Criteria:

- H.pylori negative at the time when the triple therapy is started

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01435525

Locations


Japan
Research Site
Aichi, Japan
Research Site
Akita, Japan
Research Site
Chiba, Japan
Research Site
Ehime, Japan
Research Site
Fukuoka, Japan
Research Site
Fukushima, Japan
Research Site
Gifu, Japan
Research Site
Gunma, Japan
Research Site
Hiroshima, Japan
Research Site
Hokkaido, Japan
Research Site
Hyogo, Japan
Research Site
Ibaraki, Japan
Research Site
Iwate, Japan
Research Site
Kagawa, Japan
Research Site
Kanagawa, Japan
Research Site
Kochi, Japan
Research Site
Kumamoto, Japan
Research Site
Kyoto, Japan
Research Site
Mie, Japan
Research Site
Miyagi, Japan
Research Site
Nagano, Japan
Research Site
Nagasaki, Japan
Research Site
Niigata, Japan
Research Site
Oita, Japan
Research Site
Okayama, Japan
Research Site
Okinawa, Japan
Research Site
Osaka, Japan
Research Site
Saitama, Japan
Research Site
Shiga, Japan
Research Site
Shimane, Japan
Research Site
Shizuoka, Japan
Research Site
Tokyo, Japan
Research Site
Toyama, Japan
Research Site
Wakayama, Japan
Research Site
Yamagata, Japan
Research Site
Yamanashi, Japan

Sponsors and Collaborators

AstraZeneca

Investigators


Study Director:	Shigeru Yoshida, MD	Astrazeneca K.K.

More Information

No publications provided


Responsible Party:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT01435525 History of Changes
Other Study ID Numbers:	D961HC00011
Study First Received:	September 14, 2011
Last Updated:	April 14, 2014
Health Authority:	Japan: Ministry of Health, Labor and Welfare Japan: Pharmaceuticals and Medical Devices Agency

Keywords provided by AstraZeneca:


triple therapy Helicobacter pylori eradication Nexium

Additional relevant MeSH terms:


Purpura, Thrombocytopenic Purpura, Thrombocytopenic, Idiopathic Autoimmune Diseases Blood Coagulation Disorders Blood Platelet Disorders Hematologic Diseases Hemorrhage Hemorrhagic Disorders	Immune System Diseases Pathologic Processes Purpura Signs and Symptoms Skin Manifestations Thrombocytopenia Thrombotic Microangiopathies

ClinicalTrials.gov processed this record on March 03, 2015